Latest Proton therapy Stories
PALO ALTO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Clinical studies suggest that advanced treatments like intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) are enabling radiation oncologists to enhance post-treatment health-related quality of life for patients with head and neck cancer. In an educational session for radiotherapy professionals, delivered by two noted experts during the annual meeting of the American Society for Radiation Oncology (ASTRO) in...
PALO ALTO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Researchers from the University of California, Irvine Medical Center reported last week that image-guided RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR) has clinical advantages over earlier fixed-beam approaches to stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) for treating cancer. RapidArc, Varian's technology for delivering volumetric modulated arc therapy (VMAT), enables clinicians to deliver a...
CHICAGO, Nov. 10 /PRNewswire-FirstCall/ -- Clinicians using RapidArc® radiotherapy technology for fast, precise, non-invasive cancer treatments have found that they are able to substantially reduce scatter dose to surrounding healthy tissues, according to several presentations and posters presented this week at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago. With RapidArc, doctors were able to quickly administer image-guided radiotherapy or...
MEMPHIS, Tenn., Nov. 9 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old. Under the clinical protocol, St. Jude will refer patients to receive proton therapy at the UF Proton Therapy...
Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.Researchers sought to determine if delivering higher doses of radiation with proton therapy would cause early harmful side effects to urinary function within the genitourinary system (GU) function and rectal function within the gastrointestinal...
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago. The multi-institutional, randomized trial also shows that the high dose treatment is safe for these patients and causes no...
PORTO, Portugal, Oct. 30 /PRNewswire-FirstCall/ -- Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems (NYSE: VAR) by the Instituto Portugues Oncologia, IPO Porto. The order, placed in August, includes the country's first Novalis Tx(TM) device for advanced radiosurgery and two Trilogy® medical linear accelerators offering RapidArc® radiotherapy capability. The project...
CHICAGO, Oct. 29 /PRNewswire-FirstCall/ -- ASTRO Booth # 2229 -- New technology enhancements from Varian Medical Systems (NYSE: VAR), designed to make radiotherapy and radiosurgery treatments faster, more accurate, and easier to plan and deliver, will be on display at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago next week. The Varian booth at ASTRO will provide a glimpse into the company's R&D pipeline of future technologies for managing cancer...
The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.Short-term hormone therapy added to radiation increases survival for medium-risk, but not low-risk, prostate cancer patients (late-breaking study)Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, compared to those...
International experts discussed scientific and clinical development of the innovative radiation therapyThe largest congress worldwide on the topic of particle or ion therapy "“ radiation with heavy ions and protons "“ has taken place in the fall of 2009 in Heidelberg. Well over 600 international participants, especially from Japan and the USA, convened in the Heidelberg Town Hall for the annual meeting of the "Particle Therapy Cooperative Group" (PTCOG), including leading experts from the...
